Last $20.53 USD
Change Today +1.46 / 7.66%
Volume 10.7M
HZNP On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

horizon pharma plc (HZNP) Key Developments

Horizon Pharma plc Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Revised Earnings Guidance for the Year 2015

Horizon Pharma plc announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company’s total net sales were $103.8 million, compared with $30.1 million in the fourth quarter of 2013, representing 245% year over year growth. Operating income was $8,983 million against operating loss of $5,762 million a year ago. Loss before benefit for income taxes was $34,464 million against $103,055 million a year ago. Net loss was $31,647 million against $102,901 million a year ago. Net loss per basic and diluted share was $0.27 against $1.56 a year ago. Adjusted non-GAAP net income was $35,477 or $0.27 per diluted share against adjusted non-GAAP net loss of $1,104 million or $0.02 per diluted share a year ago. EBITDA was $4.861 million against LBITDA of $97.616 million a year ago. Adjusted EBITDA was $41.006 million against adjusted LBITDA of $0.104 million a year ago. Cash provided by operating activities was $10.079 million against cash used in operating activities of $11.178 million a year ago. Non-GAAP cash provided by operating activities was $32.565 million against non-GAAP cash used in operating activities of $11.178 million a year ago. For the year, the company’s total net sales were $297.0 million, compared with $74.0 million for the full year 2013, representing 301% year over year growth. Operating loss was $8,491 million against $42,854 million a year ago. Loss before benefit for income taxes was $269,687 million against $150,126 million a year ago. Net loss was $263,603 million against $149,005 million a year ago. Net loss per basic and diluted share was $3.15 against $2.34 a year ago. Net cash provided by operating activities was $27,549 million against net cash used in operating activities was $54,287 million a year ago. Purchases of property and equipment were $3,500 million against $1,198 million a year ago. Adjusted non-GAAP net income was $92,498 million or $0.95 per diluted share against adjusted non-GAAP net loss of $36,889 million or $0.58 per diluted share a year ago. LBITDA was $192.412 million against $128.972 million a year ago. Adjusted EBITDA was $105.352 million against adjusted LBITDA of $28.254 million a year ago. Non-GAAP cash provided by operating activities was $93.185 million against non-GAAP cash used in operating activities of $54.287 million a year ago. The company revised earnings guidance for the year 2015. The company expects net sales of $450 million to $475 million and adjusted EBITDA of $170 million to $190 million against previously provided guidance of net sales of $425 million to $450 million and adjusted EBITDA of $160 million to $180 million. The company estimates an effective tax rate in the low single digits for 2015.

Horizon Pharma plc Opens New Global Corporate Headquarters in Dublin

Horizon Pharma plc announced that it has formally opened its new Global Corporate Headquarters in Dublin, located at Connaught House, Burlington Road in Dublin 4. The company plans to add sixty highly skilled jobs at its headquarter facility over the next three years.

Horizon Pharma plc Opens Chicago Office

Horizon Pharma plc announced it has opened a Chicago office. The office, which is located at 150 South Wacker Drive, will primarily house commercial, corporate analytics and business development staff.

Horizon Pharma plc Submits an Investigational New Drug Application to FDA for ACTIMMUNE in the Treatment of Friedreich's Ataxia

Horizon Pharma plc announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ACTIMMUNE in the treatment of Friedreich's Ataxia (FA). The company has simultaneously requested Fast Track Designation. The company plans to begin a Phase 3 study in the second quarter in collaboration with the Friedreich's Ataxia Research Alliance (FARA) and the investigators and clinics of FARA's Collaborative Clinical Research Network (CCRN) in FA. The Phase 3 study is expected to be a randomized, double-blind, multicenter, placebo-controlled, 26-week study evaluating ACTIMMUNE in approximately 90 male and non-pregnant female subjects between the ages of 10 and 25 years, inclusive, with an FA functional stage of greater than 1 to less than 5 and the ability to walk 25 feet with or without an assistive device. Subjects will be randomized 1:1 to receive either ACTIMMUNE or matching placebo. The primary endpoint will be the change in the Friedreich's Ataxia Rating Scale-modified neurological exam score (FARS-mNeuro), which is a measure of disease activity and correlates significantly with functional disability, from baseline to 26 weeks for patients treated with ACTIMMUNE compared to placebo. It is anticipated that it will take 18 months to completely enroll the study. A six-month open-label extension study will be offered to those FA patients completing the Phase 3 study.

Horizon Pharma plc Presents at Canaccord Genuity 2015 Rare Disease, BioPharma 1x1 Day, Feb-03-2015

Horizon Pharma plc Presents at Canaccord Genuity 2015 Rare Disease, BioPharma 1x1 Day, Feb-03-2015 .

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HZNP:US $20.53 USD +1.46

HZNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $21.95 USD -0.65
Pfizer Inc $34.32 USD -0.27
View Industry Companies
 

Industry Analysis

HZNP

Industry Average

Valuation HZNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.0x
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HORIZON PHARMA PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.